Repros Therapeutics plunges as Androxal NDA timing in question

Repros Therapeutics (RPRX) tumbles 32% premarket after outlining new FDA guidance for Androxal.

The regulator wants a meeting to discuss Site 9's inclusion in the ZA-301 analysis. RPRX notes that "ZA-302 was powered for analysis with or without Site 9 and met the co-primary endpoints in both instances." (PR)

Ultimately, RPRX is now guiding for an H2 2014 NDA submission — that looks like a delay from previous guidance of mid-2014.

The sell-side is already moving to defend the shares, with Lazard first up to bat, saying the delay is worth it, and reiterating a Buy rating. Brean is apparently also out positive.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs